R-DXd targets CDH6 in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers, showing a 46% objective response rate in a phase 1 trial. FDA breakthrough therapy designation aims to ...
Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant high-grade serous ovarian cancer (HGSOC) without CDH6 pre-selection PRINCETON, N.J., June 2, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results